MLN 4760

Drug Profile

MLN 4760

Latest Information Update: 27 Jul 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Gene Logic
  • Class Obesity therapies
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 27 Jul 2004 As part of the agreement with Millennium Pharmaceuticals, Gene Logic will investigate new therapeutic indications for MLN 4760
  • 08 Jun 2004 Discontinued - Phase-I for Obesity in United Kingdom (unspecified route)
  • 04 Jun 2004 No development reported - Phase-I for Obesity in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top